These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 28673432)

  • 1. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.
    McMahon CG; Shusterman N; Cohen B
    J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
    Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis.
    Cavender RK; Fairall M
    J Sex Med; 2009 Nov; 6(11):3177-92. PubMed ID: 19796052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
    Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
    J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
    Gittelman M; Jaffe JS; Kaminetsky JC
    J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion.
    McCullough AR; Khera M; Goldstein I; Hellstrom WJ; Morgentaler A; Levine LA
    J Sex Med; 2012 Feb; 9(2):594-601. PubMed ID: 22240203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism.
    Kaminetsky JC; Moclair B; Hemani M; Sand M
    J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
    J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone release rate and duration of action of testosterone pellet implants.
    Kelleher S; Howe C; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):420-8. PubMed ID: 15049955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
    Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
    J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants.
    Kelleher S; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):531-6. PubMed ID: 11678837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone Pellet Implantation Practices: A Sexual Medicine Society of North America (SMSNA) Member Questionnaire.
    Piecuch MJ; Patel BG; Hakim L; Wang R; Sadeghi-Nejad H
    J Sex Med; 2017 Jan; 14(1):47-49. PubMed ID: 27989489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
    Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
    J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
    Corona G; Rastrelli G; Morgentaler A; Sforza A; Mannucci E; Maggi M
    Eur Urol; 2017 Dec; 72(6):1000-1011. PubMed ID: 28434676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety outcomes of a compounded testosterone pellet versus a branded testosterone pellet in men with testosterone deficiency: a single-center, open-label, randomized trial.
    Kresch E; Lima TFN; Molina M; Deebel NA; Reddy R; Patel M; Loloi J; Carto C; Nackeeran S; Gonzalez DC; Ory J; Ramasamy R
    Sex Med; 2023 Apr; 11(2):qfad007. PubMed ID: 36936900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which testosterone replacement therapy?
    Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.
    Smith RP; Khanna A; Coward RM; Rajanahally S; Kovac JR; Gonzales MA; Lipshultz LI
    J Sex Med; 2013 Sep; 10(9):2326-33. PubMed ID: 23859250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.